Year: 2021

General

Stock price Loading… More on Euronext » General Stock Market Euronext Paris – Eurolist (compartiment B) Reuters / Bloomberg TRNG.PA / TNG.FP ISIN Code FR0005175080 Total number of shares outstanding 100,852,742 Initial Public Offering (IPO) March 26, 1998 Local Sector Index Next Biotech / CAC Mid 100 Financial Year Ends December 31

Financial reports

Years Quarter Interim Registration Document First Second Third Fourth 2023               XBRL(fr)     2022           XBRL(fr) 2021             XBRL(fr) 2020             2019             2018            … Continue reading Financial reports

Key figures

In € million except share and per share data 2022 2021 2020 2019 2018 Revenue 10.3 17.4 9.9 13.7 42.9 R&D Expense -32.2 -32.9 -27.3 -31.4 -27.3 G&A Expense -7.9 -7.4 -6.5 -7.1 -7.0 Net income (loss) -32.8 -19.5 -17.2 -18.8 8.0 Net Cash Burn -22.8 -10.0 -17.0 -20.5 -24.5 Cash & Cash Equivalents 26.8… Continue reading Key figures

produits : 5 OVs teaser

AstraZeneca Transgene and AstraZeneca have entered into a collaboration agreement under which Transgene designs five innovative oncolytic viruses based on the Invir.IO™ platform. AstraZeneca can exercise an option on each of these candidates.

produits : TG6050

TG6050 Induce an immune response against tumors resistant to available treatments TG6050 is an oncolytic virus that has been engineered to express human IL-12 and an anti-CTLA4 antibody. TG6050 has been designed to be administered intravenously. By selectively targeting tumor cells and expressing IL-12 and an anti-CTLA4 antibody in the tumor microenvironment, TG6050 is expected… Continue reading produits : TG6050

produits : BT-001 teaser

BT-001 BT-001 is the first oncolytic virus from Invir.IO™ and is optimized to act as a Trojan horse. This novel immunotherapy approach has been designed to be highly targeted and is based on the patented viral backbone (VVcop TK-RR-). Two specific “weapons” have been integrated into the Vaccinia viral DNA: an anti-CTLA4 antibody, which was… Continue reading produits : BT-001 teaser

Eric QUÉMÉNEUR

Executive Vice President and Vice President, Research & Development Eric Quéméneur joined Transgene in September 2014 as Executive Vice President in charge of Research and Development. Before joining Transgene, he spent over 20 years at the CEA (Atomic Energy Commission) where he was Director of research programs and industrial partnerships in the life science division.… Continue reading Eric QUÉMÉNEUR